A Phase 2 Study of Nab-sirolimus (ABI-009) in Patients With Advanced Malignant PEComa
Summary
The registered summary isn't in our current data snapshot. Read it on the ClinicalTrials.gov record ↗. Why? →
Investigators
The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.
- Willis Navarro, MD
Aadi Bioscience
Study Director
A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.
Sites
9 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.
- Stanford University Medical Center
Palo Alto, California, United States
- Sarcoma Oncology Research Center
Santa Monica, California, United States
- Dana-Farber Cancer Institute
Boston, Massachusetts, United States
- University of Michigan
Ann Arbor, Michigan, United States
- Washington University School of Medicine - Siteman Cancer Center
St Louis, Missouri, United States
- Memorial Sloan Kettering Cancer Center
New York, New York, United States
- Duke University Medical Center - Duke Cancer Center
Durham, North Carolina, United States
- University of Texas, Md Anderson Cancer Center
Houston, Texas, United States
- University of Washington - Seattle Cancer Care Alliance
Seattle, Washington, United States
Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.
Drugs studied
No drug or biological interventions are in our data for this study — it may test a procedure, device or behavioral intervention, or the intervention list isn't in our current snapshot. See the registry record ↗. Why? →
Registration & key dates
Registry attributes as recorded on the ClinicalTrials.gov study record.
- Start
- 31 Oct 2015
- Primary completion
- 30 Nov 2021
- Completion
- 30 Apr 2022
- Last update posted
- 7 Apr 2023
- Registered enrollment
- 34
- Registry id
- NCT02494570
Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 12 Jul 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.